Drug Trial Radar · NCT04656561
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
270
Actual
Start
Feb 26, 2021
Primary completion
Mar 28, 2023
Study completion Sep 13, 2023
Sponsor
- Lead sponsor
- Annexon, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.
Conditions
- Geographic Atrophy
Interventions
ANX007Drug
Form: solution for injection; Route of Administration: IVT
Sham comparatorOther
Form and Route of Administration: pressure to mimic IVT injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Change (Slope) From Baseline to Month 12 in GA Lesion AreaTime frame: Baseline to Month 12
Locations
53 sites in 3 countries. Site status is shown where the registry gives one.
Site 5
Phoenix, Arizona
Site 31
Bakersfield, California
Site 2
Beverly Hills, California
Site 19
Mountain View, California
Site 23
Pasadena, California
Site 37
Poway, California
Site 17
Sacramento, California
Site 18
Santa Ana, California
Site 33
Walnut Creek, California
Site 39
Waterford, Connecticut
Site 12
Fort Myers, Florida
Site 53
Jacksonville, Florida
Site 26
Pensacola, Florida
Site 16
Pinellas Park, Florida
Site 43
Sarasota, Florida
Site 28
St. Petersburg, Florida
Site 6
Winter Haven, Florida
Site 42
Augusta, Georgia
Site 11
Lexington, Kentucky
Site 1
Hagerstown, Maryland
Site 41
Hagerstown, Maryland
Site 36
Boston, Massachusetts
Site 3
Springfield, Massachusetts
Site 29
Royal Oak, Michigan
Site 10
Reno, Nevada
Site 38
Bloomfield, New Jersey
Site 9
Cherry Hill, New Jersey
Site 30
Albuquerque, New Mexico
Site 20
Asheville, North Carolina
Site 52
Cleveland, Ohio
Site 13
Edmond, Oklahoma
Site 40
Eugene, Oregon
Site 27
Philadelphia, Pennsylvania
Site 15
Abilene, Texas
Site 4
Austin, Texas
Site 24
Bellaire, Texas
Site 34
Burleson, Texas
Site 21
Dallas, Texas
Site 32
Fort Worth, Texas
Site 22
Fort Worth, Texas
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.